APEIRON Biologics
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 7.9m | 9.2m | 11.0m | 13.8m | 13.8m | 13.8m |
| % growth | - | 17 % | 19 % | 25 % | - | - |
| EBITDA | (5.0m) | (2.6m) | (5.2m) | 1.8m | - | - |
| % EBITDA margin | (63 %) | (28 %) | (47 %) | 13 % | - | - |
| Profit | (5.4m) | (3.0m) | (5.5m) | 1.5m | - | - |
| % profit margin | (69 %) | (33 %) | (50 %) | 11 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€25.0m | Debt | ||
| N/A | N/A | - | |
* | $100m Valuation: $100m | Acquisition | |
| Total Funding | - | ||
Recent News about APEIRON Biologics
EditApeiron Biologics is a biotechnology company specializing in the development of innovative immuno-oncology therapies aimed at treating various forms of cancer. The company operates in the highly competitive biopharmaceutical market and primarily serves healthcare providers, research institutions, and pharmaceutical companies. Apeiron Biologics' business model focuses on research and development (R&D), leveraging advanced biotechnology to create novel treatments. Revenue is generated through partnerships, licensing agreements, and the commercialization of proprietary therapies. Since January 2022, the company's R&D portfolio has been managed by its 100% subsidiary, invIOs, which focuses on pioneering new cancer treatments.
Keywords: immuno-oncology, cancer therapy, biotechnology, R&D, healthcare, pharmaceutical, partnerships, licensing, commercialization, invIOs.